HALO Logo

Halozyme Therapeutics, Inc. (HALO) 

NASDAQ
Market Cap
$6.26B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
690 of 966
Rank in Industry
385 of 554

Largest Insider Buys in Sector

HALO Stock Price History Chart

HALO Stock Performance

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Insider Activity of Halozyme Therapeutics, Inc.

Over the last 12 months, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $20.39M worth of Halozyme Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Halozyme Therapeutics, Inc. have bought $748,697 and sold $16.34M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 52,629 shares for transaction amount of $748,697 was made by Kelley Kenneth J (director) on 2020‑03‑19.

List of Insider Buy and Sell Transactions, Halozyme Therapeutics, Inc.

2024-10-16SaleSVP, CHIEF TECHNICAL OFFICER
10,000
0.0074%
$53.26$532,590-5.41%
2024-10-15SaleSVP, CHIEF TECHNICAL OFFICER
10,000
0.0075%
$53.75$537,469-6.02%
2024-10-09SalePRESIDENT AND CEO
10,000
0.0073%
$52.58$525,783+1.08%
2024-10-08SalePRESIDENT AND CEO
10,000
0.0075%
$54.00$539,961-6.41%
2024-09-26SalePRESIDENT AND CEO
10,000
0.0076%
$56.10$560,970+1.52%
2024-09-25SalePRESIDENT AND CEO
10,000
0.0076%
$56.34$563,370+1.09%
2024-09-24SalePRESIDENT AND CEO
10,000
0.0079%
$58.21$582,100-2.16%
2024-09-18SaleSVP, CHIEF TECHNICAL OFFICER
10,000
0.0079%
$62.03$620,316-14.57%
2024-09-17SaleSVP, CHIEF TECHNICAL OFFICER
10,000
0.008%
$62.88$628,780-13.68%
2024-09-12SalePRESIDENT AND CEO
10,000
0.0077%
$59.20$592,030-11.08%
2024-09-11SalePRESIDENT AND CEO
10,000
0.0079%
$59.09$590,870+2.46%
2024-09-10SalePRESIDENT AND CEO
10,000
0.0079%
$59.09$590,890-9.13%
2024-08-21SaleSVP, CHIEF TECHNICAL OFFICER
10,000
0.0078%
$61.75$617,470-7.19%
2024-08-20SaleSVP, CHIEF TECHNICAL OFFICER
10,000
0.0079%
$61.05$610,550-4.55%
2024-08-15SalePRESIDENT AND CEO
10,000
0.0082%
$57.95$579,4900.00%
2024-08-14SalePRESIDENT AND CEO
10,000
0.0081%
$57.25$572,4710.00%
2024-08-14Saledirector
9,881
0.0081%
$57.70$570,1340.00%
2024-08-13SalePRESIDENT AND CEO
10,000
0.0079%
$56.25$562,4900.00%
2024-08-13Saledirector
10,000
0.0079%
$56.19$561,9300.00%
2024-08-12Saledirector
10,000
0.0079%
$55.72$557,230+4.28%

Insider Historical Profitability

72.81%
Torley HelenPRESIDENT AND CEO
676744
0.5319%
$49.19144+68.25%
LaBarre Michael J.SVP, CHIEF TECHNICAL OFFICER
173756
0.1366%
$49.19045
Posard Matthew L.director
69874
0.0549%
$49.1908
LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER
15480
0.0122%
$49.1906
Frost Gregory IanCEO, President
3555331
2.7945%
$49.19416+20.07%
KIRK RANDAL J10 percent owner
1897610
1.4915%
$49.195618+103.31%
Lim Jonathan EPresident, CEO
680000
0.5345%
$49.1918+18.01%
RAMSAY DAVID AVP and Chief Financial Officer
323492
0.2543%
$49.1973+24.44%
FALBERG KATHRYN Edirector
280000
0.2201%
$49.1930+46.53%
Engler Robertdirector
273176
0.2147%
$49.1953+18.07%
MATSUI CONNIEdirector
181983
0.143%
$49.1902
PATTON JOHN STUARTdirector
179876
0.1414%
$49.19022
Kelley Kenneth Jdirector
179833
0.1413%
$49.19322+50.56%
Yocum Richard CVP Clinical Development
65975
0.0519%
$49.1901
BIZZARI JEAN-PIERREdirector
52544
0.0413%
$49.1901
Henderson Jeffrey Williamdirector
39045
0.0307%
$49.1903
Chondros DimitriosSVP, Chief Medical Officer
38584
0.0303%
$49.1902
Shaffer James PVP & Chief Commercial Officer
26300
0.0207%
$49.1910+34.32%
Daly James Mdirector
20503
0.0161%
$49.1904
Thornton Steven Tdirector
15000
0.0118%
$49.1903
Shepard H. MichaelVP, Chief Scientific Officer
13198
0.0104%
$49.1901
LITTLE ROBERT JVP, Chief Commercial Officer
13000
0.0102%
$49.1920<0.0001%
Stelzer LaurieChief Financial Officer
10000
0.0079%
$49.1910<0.0001%
GUSTAFSON KURT AVice President and CFO
8000
0.0063%
$49.1910
Kennard Don AVice President, Regulatory Aff
3000
0.0024%
$49.1910+31.79%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$742.07M14.3318.24M-2.09%-$15.84M0.02
The Vanguard Group$530.84M10.2513.05M-1.59%-$8.55M0.01
State Street$263.9M5.16.49M+0.18%+$478,152.720.01
Right Side Capital Management$167.49M3.244.12M+10.99%+$16.58M3.59
Artisan Partners$154.23M2.983.79M-43.32%-$117.88M0.23
AllianceBernstein$149.15M2.883.67M+5.85%+$8.24M0.05
JPMorgan Chase$131.82M2.553.24M+4.74%+$5.96M0.01
Geode Capital Management$123.17M2.383.03M+3.69%+$4.38M0.01
Macquarie Group$121.68M2.352.99M-8.88%-$11.86M0.11
Td Asset Management Inc$103.38M22.54M+28.09%+$22.67M0.09
GW&K Investment Management$89.37M1.732.2M-1.33%-$1.21M0.79
Invesco$84.96M1.642.09M+2.85%+$2.35M0.02
Arrowmark Colorado Holdings Llc$75.62M1.461.86M+17.94%+$11.5M0.19
Northern Trust$72.89M1.411.79M-9.21%-$7.4M0.01
Thrivent Financial For Lutherans$69.76M1.351.71M-10.76%-$8.41M0.15
Bank of America$69.04M1.331.7M+42.9%+$20.73M0.01
Dimensional Fund Advisors$68.68M1.331.69M+4.66%+$3.06M0.02
Charles Schwab$67.83M1.311.67M-3.95%-$2.79M0.02
Nuveen$67.19M1.31.65M+8.29%+$5.14M0.02
Stephens Investment Management Group LLC$62.92M1.221.55M+1.86%+$1.15M0.84
Epoch Investment Partners Inc$58.32M1.131.43M+23.27%+$11.01M0.26
Morgan Stanley$55.14M1.071.36M+5.8%+$3.02M<0.01
T. Rowe Price$52.84M1.021.3M-6.55%-$3.7M0.01
BNY Mellon$49.39M0.951.21M-6.13%-$3.23M0.01
First Trust$48.59M0.941.19M+1,200.58%+$44.85M0.05
New York State Common Retirement Fund$37.33M0.72917,759-3.33%-$1.28M0.05
Handelsbanken$33.71M0.65828,669+236.76%+$23.7M0.15
Goldman Sachs$33.41M0.65821,386-46.72%-$29.3M0.01
Granite Investment Partners Llc$33.01M0.64811,458-2.52%-$852,815.511.25
LAZARD ASSET MANAGEMENT LLC$32.79M0.63805,975-10.18%-$3.72M0.04
American Century Investments$30.46M0.59748,722+5.27%+$1.52M0.02
Allspring Global Investments$28.32M0.55696,127-4.38%-$1.3M0.05
Wells Fargo$25.92M0.5637,276-2.96%-$789,517.910.01
Boston Partners$25.5M0.5630,368+14.12%+$3.15M0.03
Silvercrest Asset Management Group Inc$24.54M0.47603,137+2%+$480,227.400.17
Fuller & Thaler Asset Management, Inc.$23.12M0.45568,361+38.73%+$6.46M0.1
Janus Henderson$21.6M0.42531,125+24.03%+$4.19M0.01
Bank of Montreal$21.18M0.41519,430+2.95%+$606,983.790.01
2Xideas$20.97M0.41515,462-5.28%-$1.17M2.57
Kennedy Capital Management Inc$20.87M0.4513,096-22.59%-$6.09M0.44
Federated Hermes$20.55M0.4505,101+9.96%+$1.86M0.05
Royal Bank of Canada$19.96M0.39490,665-1.81%-$367,579.840.01
Kornitzer Capital Management Inc Ks$19.74M0.38485,234+2.21%+$427,140.000.36
LSV Asset Management$18.79M0.36461,800-0.13%-$24,407.970.04
Mizuho Markets Americas Llc$18.58M0.36456,636+2.23%+$405,782.990.42
Renaissance Technologies$17.55M0.34431,380+123.07%+$9.68M0.03
RhumbLine Advisers$17.57M0.34431,828+0.62%+$108,371.350.02
Congress Asset Management Co Ma$16.59M0.32407,867+16.18%+$2.31M0.12
Man Group Plc$16.27M0.31400,068+15.03%+$2.13M0.04
Voloridge Investment Management, LLC$16.2M0.31398,306+627.71%+$13.98M0.06
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.